CA3070756A1 - Compounds which specifically bind to cd38 for use in the treatment of neurodegenerative and inflammatory diseases - Google Patents

Info

Publication number

CA3070756A1

CA3070756A1 CA3070756A CA3070756A CA3070756A1 CA 3070756 A1 CA3070756 A1 CA 3070756A1 CA 3070756 A CA3070756 A CA 3070756A CA 3070756 A CA3070756 A CA 3070756A CA 3070756 A1 CA3070756 A1 CA 3070756A1

Authority

CA

Canada

Prior art keywords

compound

disease

antibody

naadp

amino

Prior art date

2017-07-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 153
• 238000011282 treatment Methods 0.000 title claims abstract description 72
• 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 52
• 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 41
• 230000000626 neurodegenerative effect Effects 0.000 title description 32
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims abstract description 185
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims abstract description 144
• 239000003814 drug Substances 0.000 claims abstract description 70
• 101000679525 Homo sapiens Two pore channel protein 2 Proteins 0.000 claims abstract description 46
• 102100022609 Two pore channel protein 2 Human genes 0.000 claims abstract description 44
• 101000763003 Homo sapiens Two pore channel protein 1 Proteins 0.000 claims abstract description 43
• 239000011148 porous material Substances 0.000 claims abstract description 42
• 230000004770 neurodegeneration Effects 0.000 claims abstract description 32
• 230000002265 prevention Effects 0.000 claims abstract description 17
• 230000027455 binding Effects 0.000 claims description 119
• 239000000427 antigen Substances 0.000 claims description 105
• 108091007433 antigens Proteins 0.000 claims description 105
• 102000036639 antigens Human genes 0.000 claims description 105
• 230000000694 effects Effects 0.000 claims description 73
• 239000012634 fragment Substances 0.000 claims description 69
• 102000005962 receptors Human genes 0.000 claims description 68
• 108020003175 receptors Proteins 0.000 claims description 68
• 210000002569 neuron Anatomy 0.000 claims description 63
• 102000052645 human CD38 Human genes 0.000 claims description 42
• 238000000034 method Methods 0.000 claims description 42
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
• 150000001413 amino acids Chemical class 0.000 claims description 28
• 102000004169 proteins and genes Human genes 0.000 claims description 28
• 108090000623 proteins and genes Proteins 0.000 claims description 28
• 235000018102 proteins Nutrition 0.000 claims description 26
• 235000018417 cysteine Nutrition 0.000 claims description 25
• 208000035475 disorder Diseases 0.000 claims description 24
• 235000001014 amino acid Nutrition 0.000 claims description 23
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 21
• 239000003795 chemical substances by application Substances 0.000 claims description 20
• 208000018737 Parkinson disease Diseases 0.000 claims description 17
• 238000004458 analytical method Methods 0.000 claims description 16
• 102000004157 Hydrolases Human genes 0.000 claims description 14
• 108090000604 Hydrolases Proteins 0.000 claims description 14
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
• 206010012289 Dementia Diseases 0.000 claims description 13
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 13
• 201000010099 disease Diseases 0.000 claims description 13
• 230000003834 intracellular effect Effects 0.000 claims description 13
• 229940124597 therapeutic agent Drugs 0.000 claims description 13
• 210000004899 c-terminal region Anatomy 0.000 claims description 11
• 201000006417 multiple sclerosis Diseases 0.000 claims description 11
• 208000024827 Alzheimer disease Diseases 0.000 claims description 10
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 10
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 10
• 230000003213 activating effect Effects 0.000 claims description 10
• 239000004480 active ingredient Substances 0.000 claims description 10
• 235000013922 glutamic acid Nutrition 0.000 claims description 10
• 239000004220 glutamic acid Substances 0.000 claims description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
• 208000027089 Parkinsonian disease Diseases 0.000 claims description 9
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 9
• 208000011580 syndromic disease Diseases 0.000 claims description 9
• 208000015872 Gaucher disease Diseases 0.000 claims description 8
• 230000002401 inhibitory effect Effects 0.000 claims description 8
• 239000004090 neuroprotective agent Substances 0.000 claims description 8
• 208000023105 Huntington disease Diseases 0.000 claims description 7
• 125000002228 disulfide group Chemical group 0.000 claims description 7
• 208000006454 hepatitis Diseases 0.000 claims description 7
• 239000006041 probiotic Substances 0.000 claims description 7
• 235000018291 probiotics Nutrition 0.000 claims description 7
• 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 6
• 208000024412 Friedreich ataxia Diseases 0.000 claims description 6
• 208000015439 Lysosomal storage disease Diseases 0.000 claims description 6
• 208000001089 Multiple system atrophy Diseases 0.000 claims description 6
• 206010034010 Parkinsonism Diseases 0.000 claims description 6
• 208000024777 Prion disease Diseases 0.000 claims description 6
• 210000002865 immune cell Anatomy 0.000 claims description 6
• 208000005264 motor neuron disease Diseases 0.000 claims description 6
• 201000008752 progressive muscular atrophy Diseases 0.000 claims description 6
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
• 102100032187 Androgen receptor Human genes 0.000 claims description 5
• 208000023275 Autoimmune disease Diseases 0.000 claims description 5
• 208000001640 Fibromyalgia Diseases 0.000 claims description 5
• 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
• 208000016604 Lyme disease Diseases 0.000 claims description 5
• 208000006011 Stroke Diseases 0.000 claims description 5
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 5
• 235000003704 aspartic acid Nutrition 0.000 claims description 5
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
• 231100000283 hepatitis Toxicity 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• 208000002320 spinal muscular atrophy Diseases 0.000 claims description 5
• 201000007848 Arts syndrome Diseases 0.000 claims description 4
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 4
• 208000000094 Chronic Pain Diseases 0.000 claims description 4
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 4
• 206010020751 Hypersensitivity Diseases 0.000 claims description 4
• 208000002193 Pain Diseases 0.000 claims description 4
• 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
• 208000018839 Wilson disease Diseases 0.000 claims description 4
• 230000007815 allergy Effects 0.000 claims description 4
• 239000013066 combination product Substances 0.000 claims description 4
• 229940127555 combination product Drugs 0.000 claims description 4
• 210000004558 lewy body Anatomy 0.000 claims description 4
• 230000009529 traumatic brain injury Effects 0.000 claims description 4
• 208000036022 Alpers' disease Diseases 0.000 claims description 3
• 108700033847 Alpha-Methylacyl-CoA Racemase Deficiency Proteins 0.000 claims description 3
• 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 3
• 102000004321 Atrophin-1 Human genes 0.000 claims description 3
• 108090000806 Atrophin-1 Proteins 0.000 claims description 3
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
• 206010003805 Autism Diseases 0.000 claims description 3
• 208000020706 Autistic disease Diseases 0.000 claims description 3
• 208000016560 COFS syndrome Diseases 0.000 claims description 3
• 208000010200 Cockayne syndrome Diseases 0.000 claims description 3
• 208000035336 Corpus callosum agenesis-neuronopathy syndrome Diseases 0.000 claims description 3
• 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 claims description 3
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 3
• 201000010374 Down Syndrome Diseases 0.000 claims description 3
• 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 claims description 3
• 208000025329 Fazio-Londe disease Diseases 0.000 claims description 3
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 3
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims description 3
• 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 claims description 3
• 208000006264 Korsakoff syndrome Diseases 0.000 claims description 3
• 208000006136 Leigh Disease Diseases 0.000 claims description 3
• 208000017507 Leigh syndrome Diseases 0.000 claims description 3
• 208000037795 Lethal ataxia with deafness and optic atrophy Diseases 0.000 claims description 3
• 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
• 201000002832 Lewy body dementia Diseases 0.000 claims description 3
• 208000036397 Mitochondrial membrane protein-associated neurodegeneration Diseases 0.000 claims description 3
• 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
• 208000021320 Nasu-Hakola disease Diseases 0.000 claims description 3
• 208000027626 Neurocognitive disease Diseases 0.000 claims description 3
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims description 3
• 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 claims description 3
• 206010033892 Paraplegia Diseases 0.000 claims description 3
• 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims description 3
• 208000010291 Primary Progressive Nonfluent Aphasia Diseases 0.000 claims description 3
• 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 3
• 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims description 3
• 206010063837 Reperfusion injury Diseases 0.000 claims description 3
• 208000018642 Semantic dementia Diseases 0.000 claims description 3
• 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 claims description 3
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
• 208000032930 Spastic paraplegia Diseases 0.000 claims description 3
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
• 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 3
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
• 208000016620 Tourette disease Diseases 0.000 claims description 3
• 206010052779 Transplant rejections Diseases 0.000 claims description 3
• 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 3
• 201000004810 Vascular dementia Diseases 0.000 claims description 3
• 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 3
• 201000003225 agenesis of the corpus callosum with peripheral neuropathy Diseases 0.000 claims description 3
• 208000026935 allergic disease Diseases 0.000 claims description 3
• 201000000673 alpha-methylacyl-CoA racemase deficiency Diseases 0.000 claims description 3
• 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 claims description 3
• 208000006673 asthma Diseases 0.000 claims description 3
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
• 208000029560 autism spectrum disease Diseases 0.000 claims description 3
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 3
• 208000010877 cognitive disease Diseases 0.000 claims description 3
• 201000010901 lateral sclerosis Diseases 0.000 claims description 3
• 208000036546 leukodystrophy Diseases 0.000 claims description 3
• 206010027175 memory impairment Diseases 0.000 claims description 3
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
• 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 claims description 3
• 201000001119 neuropathy Diseases 0.000 claims description 3
• 230000007823 neuropathy Effects 0.000 claims description 3
• 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 3
• 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 claims description 3
• 208000014670 posterior cortical atrophy Diseases 0.000 claims description 3
• 201000002241 progressive bulbar palsy Diseases 0.000 claims description 3
• 201000000196 pseudobulbar palsy Diseases 0.000 claims description 3
• 201000000980 schizophrenia Diseases 0.000 claims description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
• QOTXBMGJKFVZRD-HISDBWNOSA-O nicotinic acid-adenine dinucleotide phosphate Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)OP(O)(O)=O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 QOTXBMGJKFVZRD-HISDBWNOSA-O 0.000 claims 4
• 108091006146 Channels Proteins 0.000 abstract description 4
• BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 81
• 229950006238 nadide Drugs 0.000 description 69
• 230000000324 neuroprotective effect Effects 0.000 description 67
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 58
• -1 i.e. Proteins 0.000 description 54
• DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 52
• QOTXBMGJKFVZRD-HISDBWNOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)OP(O)(O)=O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 QOTXBMGJKFVZRD-HISDBWNOSA-N 0.000 description 51
• 239000003112 inhibitor Substances 0.000 description 49
• 210000004027 cell Anatomy 0.000 description 47
• 230000003291 dopaminomimetic effect Effects 0.000 description 45
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 42
• FUHCEERDBRGPQZ-LBNVMWSVSA-N trans-Ned 19 Chemical compound COC1=CC=C([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H](N2)C(O)=O)C=C1CN(CC1)CCN1C1=CC=CC=C1F FUHCEERDBRGPQZ-LBNVMWSVSA-N 0.000 description 33
• 208000031752 chronic bilirubin encephalopathy Diseases 0.000 description 32
• 238000010172 mouse model Methods 0.000 description 32
• 238000001727 in vivo Methods 0.000 description 29
• 238000003556 assay Methods 0.000 description 27
• 239000000203 mixture Substances 0.000 description 27
• 210000005064 dopaminergic neuron Anatomy 0.000 description 26
• 238000002347 injection Methods 0.000 description 25
• 239000007924 injection Substances 0.000 description 25
• 230000004913 activation Effects 0.000 description 24
• 239000008194 pharmaceutical composition Substances 0.000 description 24
• 210000001259 mesencephalon Anatomy 0.000 description 23
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 22
• 239000011575 calcium Substances 0.000 description 22
• 229910052791 calcium Inorganic materials 0.000 description 22
• 230000001086 cytosolic effect Effects 0.000 description 22
• 102000003814 Interleukin-10 Human genes 0.000 description 21
• 108090000174 Interleukin-10 Proteins 0.000 description 21
• 230000001965 increasing effect Effects 0.000 description 21
• 229940076144 interleukin-10 Drugs 0.000 description 21
• 230000002025 microglial effect Effects 0.000 description 20
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 19
• 230000002132 lysosomal effect Effects 0.000 description 19
• BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 18
• 241001465754 Metazoa Species 0.000 description 18
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 18
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 18
• 230000000875 corresponding effect Effects 0.000 description 17
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
• GYBHRTQLUQOYID-UHFFFAOYSA-N quinazoline-8-carboxamide Chemical compound N1=CN=C2C(C(=O)N)=CC=CC2=C1 GYBHRTQLUQOYID-UHFFFAOYSA-N 0.000 description 16
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 16
• PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 15
• 230000003110 anti-inflammatory effect Effects 0.000 description 15
• 230000001054 cortical effect Effects 0.000 description 15
• 230000004224 protection Effects 0.000 description 15
• 210000003523 substantia nigra Anatomy 0.000 description 15
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 14
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 14
• 210000004556 brain Anatomy 0.000 description 14
• 230000030833 cell death Effects 0.000 description 14
• 210000003618 cortical neuron Anatomy 0.000 description 14
• 238000000338 in vitro Methods 0.000 description 14
• 230000004112 neuroprotection Effects 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 13
• 230000003492 excitotoxic effect Effects 0.000 description 13
• 241001573498 Compacta Species 0.000 description 12
• 230000002121 endocytic effect Effects 0.000 description 12
• 239000002953 phosphate buffered saline Substances 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 11
• 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 11
• 241000699670 Mus sp. Species 0.000 description 11
• 230000008499 blood brain barrier function Effects 0.000 description 11
• 210000001218 blood-brain barrier Anatomy 0.000 description 11
• 230000004190 glucose uptake Effects 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 10
• 150000001408 amides Chemical class 0.000 description 10
• 210000001130 astrocyte Anatomy 0.000 description 10
• 231100000063 excitotoxicity Toxicity 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• GQWYWHOHRVVHAP-UHFFFAOYSA-N jasplakinolide Natural products C1C(=O)OC(C)CC(C)C=C(C)CC(C)C(=O)NC(C)C(=O)N(C)C(CC=2C3=CC=CC=C3NC=2Br)C(=O)NC1C1=CC=C(O)C=C1 GQWYWHOHRVVHAP-UHFFFAOYSA-N 0.000 description 10
• 230000002438 mitochondrial effect Effects 0.000 description 10
• 230000036542 oxidative stress Effects 0.000 description 10
• 230000004083 survival effect Effects 0.000 description 10
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
• 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 9
• 108091034117 Oligonucleotide Proteins 0.000 description 9
• 230000001363 autoimmune Effects 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 9
• 239000013642 negative control Substances 0.000 description 9
• 230000002269 spontaneous effect Effects 0.000 description 9
• 230000001419 dependent effect Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
• 238000010253 intravenous injection Methods 0.000 description 8
• GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical group C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 8
• 108010052440 jasplakinolide Proteins 0.000 description 8
• 208000008795 neuromyelitis optica Diseases 0.000 description 8
• 102000001424 Ryanodine receptors Human genes 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 230000001154 acute effect Effects 0.000 description 7
• 229960004046 apomorphine Drugs 0.000 description 7
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 230000007850 degeneration Effects 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 239000012636 effector Substances 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 230000000670 limiting effect Effects 0.000 description 7
• 210000003712 lysosome Anatomy 0.000 description 7
• 230000001868 lysosomic effect Effects 0.000 description 7
• 230000035800 maturation Effects 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical group C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 6
• 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 6
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• 108010017544 Glucosylceramidase Proteins 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 206010028980 Neoplasm Diseases 0.000 description 6
• 101710138657 Neurotoxin Proteins 0.000 description 6
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 229960001987 dantrolene Drugs 0.000 description 6
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 6
• 229930195712 glutamate Natural products 0.000 description 6
• 206010025135 lupus erythematosus Diseases 0.000 description 6
• 239000002581 neurotoxin Substances 0.000 description 6
• 231100000618 neurotoxin Toxicity 0.000 description 6
• 230000000750 progressive effect Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 230000001960 triggered effect Effects 0.000 description 6
• SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 5
• SRNWOUGRCWSEMX-UHFFFAOYSA-N Adenosine diphosphate ribose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OCC1OC(O)C(O)C1O SRNWOUGRCWSEMX-UHFFFAOYSA-N 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 5
• 101000927265 Hyas araneus Arasin 2 Proteins 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 5
• 102100026736 Two pore channel protein 1 Human genes 0.000 description 5
• 230000002378 acidificating effect Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
• RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 description 5
• 230000006735 deficit Effects 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 230000028023 exocytosis Effects 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 238000007913 intrathecal administration Methods 0.000 description 5
• 230000007309 lysosomal acidification Effects 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 210000001577 neostriatum Anatomy 0.000 description 5
• 235000001968 nicotinic acid Nutrition 0.000 description 5
• 239000011664 nicotinic acid Substances 0.000 description 5
• 229960003512 nicotinic acid Drugs 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 208000008190 Agammaglobulinemia Diseases 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
• 208000021866 Dressler syndrome Diseases 0.000 description 4
• 208000007465 Giant cell arteritis Diseases 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 4
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 4
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 102000004877 Insulin Human genes 0.000 description 4
• 108090001061 Insulin Proteins 0.000 description 4
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 4
• 201000002481 Myositis Diseases 0.000 description 4
• 208000003435 Optic Neuritis Diseases 0.000 description 4
• 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 4
• 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 4
• 206010034277 Pemphigoid Diseases 0.000 description 4
• 108010079855 Peptide Aptamers Proteins 0.000 description 4
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
• 229940121858 Sirtuin 1 inhibitor Drugs 0.000 description 4
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 150000001945 cysteines Chemical class 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 229960003638 dopamine Drugs 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 230000012202 endocytosis Effects 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 239000012894 fetal calf serum Substances 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 229940125396 insulin Drugs 0.000 description 4
• 230000035987 intoxication Effects 0.000 description 4
• 231100000566 intoxication Toxicity 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 206010065579 multifocal motor neuropathy Diseases 0.000 description 4
• 201000003631 narcolepsy Diseases 0.000 description 4
• 230000016273 neuron death Effects 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 4
• 229940044551 receptor antagonist Drugs 0.000 description 4
• 239000002464 receptor antagonist Substances 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 206010043207 temporal arteritis Diseases 0.000 description 4
• 208000009174 transverse myelitis Diseases 0.000 description 4
• QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 3
• ZRJRBVIDGZTSRA-UHFFFAOYSA-N 2-methyl-4-[(2-methylphenyl)methylamino]quinoline-8-carboxamide Chemical compound CC1=NC2=C(C=CC=C2C(=C1)NCC1=C(C=CC=C1)C)C(=O)N ZRJRBVIDGZTSRA-UHFFFAOYSA-N 0.000 description 3
• JMEJTSRAQUFNOP-TURZUDJPSA-N 4-n-[(e)-(3-iodophenyl)methylideneamino]-6-morpholin-4-yl-2-n,2-n-diphenyl-1,3,5-triazine-2,4-diamine Chemical compound IC1=CC=CC(\C=N\NC=2N=C(N=C(N=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCOCC2)=C1 JMEJTSRAQUFNOP-TURZUDJPSA-N 0.000 description 3
• 229940126634 CD38 inhibitor Drugs 0.000 description 3
• VJQALSOBHVEJQM-UHFFFAOYSA-N COCCOC1CCC(CC1)Nc1cc(=O)n(C)c2ccc(cc12)-c1cncs1 Chemical compound COCCOC1CCC(CC1)Nc1cc(=O)n(C)c2ccc(cc12)-c1cncs1 VJQALSOBHVEJQM-UHFFFAOYSA-N 0.000 description 3
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 102000007072 Nerve Growth Factors Human genes 0.000 description 3
• 101100481912 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tpc-1 gene Proteins 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 229950008995 aducanumab Drugs 0.000 description 3
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 239000003146 anticoagulant agent Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000006727 cell loss Effects 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 231100000318 excitotoxic Toxicity 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 230000010534 mechanism of action Effects 0.000 description 3
• 239000003900 neurotrophic factor Substances 0.000 description 3
• 239000011570 nicotinamide Substances 0.000 description 3
• 229960003966 nicotinamide Drugs 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 230000006320 pegylation Effects 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 238000002702 ribosome display Methods 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 238000007619 statistical method Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
• XDHNQDDQEHDUTM-ZGOPVUMHSA-N (7R,8S,9S,15S,16R)-16-[(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one Chemical compound CO[C@H]1C=CC=C(C)C[C@H](C)[C@H](O)[C@H](C)C=C(C)C=C(OC)C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-ZGOPVUMHSA-N 0.000 description 2
• AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 2
• UXMBUALLBSVFNJ-UHFFFAOYSA-N 4-[(2-chloro-3,6-difluorophenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1F)F UXMBUALLBSVFNJ-UHFFFAOYSA-N 0.000 description 2
• WWCLIIDYSGNTQD-UHFFFAOYSA-N 4-[[[2-(benzylamino)-2-oxoethyl]-[4-(dimethylamino)benzoyl]amino]methyl]-N-hydroxybenzamide Chemical compound CN(C)c1ccc(cc1)C(=O)N(CC(=O)NCc1ccccc1)Cc1ccc(cc1)C(=O)NO WWCLIIDYSGNTQD-UHFFFAOYSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 102000000074 ADP-ribosyl Cyclase Human genes 0.000 description 2
• 108010080394 ADP-ribosyl Cyclase Proteins 0.000 description 2
• 208000026872 Addison Disease Diseases 0.000 description 2
• IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
• 206010001935 American trypanosomiasis Diseases 0.000 description 2
• 208000028185 Angioedema Diseases 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 108091023037 Aptamer Proteins 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 206010003267 Arthritis reactive Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010003591 Ataxia Diseases 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 206010064539 Autoimmune myocarditis Diseases 0.000 description 2
• 206010069002 Autoimmune pancreatitis Diseases 0.000 description 2
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
• 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 2
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
• 201000002829 CREST Syndrome Diseases 0.000 description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 description 2
• 208000005024 Castleman disease Diseases 0.000 description 2
• 208000024699 Chagas disease Diseases 0.000 description 2
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
• 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 2
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 208000010007 Cogan syndrome Diseases 0.000 description 2
• 208000011038 Cold agglutinin disease Diseases 0.000 description 2
• 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 2
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
• 206010011258 Coxsackie myocarditis Diseases 0.000 description 2
• FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 2
• 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 2
• 201000009273 Endometriosis Diseases 0.000 description 2
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 2
• 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 2
• 206010015226 Erythema nodosum Diseases 0.000 description 2
• 208000000289 Esophageal Achalasia Diseases 0.000 description 2
• 208000004332 Evans syndrome Diseases 0.000 description 2
• 101150028412 GBA gene Proteins 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 208000024869 Goodpasture syndrome Diseases 0.000 description 2
• 208000003807 Graves Disease Diseases 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 208000001204 Hashimoto Disease Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 206010019263 Heart block congenital Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
• 206010019939 Herpes gestationis Diseases 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
• 208000031814 IgA Vasculitis Diseases 0.000 description 2
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
• 208000021330 IgG4-related disease Diseases 0.000 description 2
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 2
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
• 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 2
• 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 102000003815 Interleukin-11 Human genes 0.000 description 2
• 108090000177 Interleukin-11 Proteins 0.000 description 2
• 102000003816 Interleukin-13 Human genes 0.000 description 2
• 108090000176 Interleukin-13 Proteins 0.000 description 2
• 102100030703 Interleukin-22 Human genes 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 208000005615 Interstitial Cystitis Diseases 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 description 2
• 208000011200 Kawasaki disease Diseases 0.000 description 2
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
• 206010024434 Lichen sclerosus Diseases 0.000 description 2
• 208000012309 Linear IgA disease Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 201000010991 Marinesco-Sjogren syndrome Diseases 0.000 description 2
• 208000027530 Meniere disease Diseases 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
• 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
• 208000024599 Mooren ulcer Diseases 0.000 description 2
• 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 2
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
• AYIAFDDGJPNRDW-RFVHGSKJSA-N OC(=O)C(F)(F)F.C[C@@H](O)c1n[nH]c2CN(Cc12)c1nc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1 Chemical compound OC(=O)C(F)(F)F.C[C@@H](O)c1n[nH]c2CN(Cc12)c1nc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1 AYIAFDDGJPNRDW-RFVHGSKJSA-N 0.000 description 2
• AYIAFDDGJPNRDW-MERQFXBCSA-N OC(=O)C(F)(F)F.C[C@H](O)c1n[nH]c2CN(Cc12)c1nc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1 Chemical compound OC(=O)C(F)(F)F.C[C@H](O)c1n[nH]c2CN(Cc12)c1nc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1 AYIAFDDGJPNRDW-MERQFXBCSA-N 0.000 description 2
• 206010030136 Oesophageal achalasia Diseases 0.000 description 2
• YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 2
• 206010053869 POEMS syndrome Diseases 0.000 description 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
• 208000008223 Pemphigoid Gestationis Diseases 0.000 description 2
• 241000721454 Pemphigus Species 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
• 208000000766 Pityriasis Lichenoides Diseases 0.000 description 2
• 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 2
• 206010065159 Polychondritis Diseases 0.000 description 2
• 229920002873 Polyethylenimine Polymers 0.000 description 2
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
• 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 2
• 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 208000012322 Raynaud phenomenon Diseases 0.000 description 2
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
• 208000005793 Restless legs syndrome Diseases 0.000 description 2
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 2
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
• 206010039705 Scleritis Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 2
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
• 206010042276 Subacute endocarditis Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• 206010071574 Testicular autoimmunity Diseases 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 2
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
• 241000223109 Trypanosoma cruzi Species 0.000 description 2
• 208000026928 Turner syndrome Diseases 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 2
• 206010064996 Ulcerative keratitis Diseases 0.000 description 2
• 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
• 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
• 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 206010047642 Vitiligo Diseases 0.000 description 2
• 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 201000000621 achalasia Diseases 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 208000004631 alopecia areata Diseases 0.000 description 2
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
• 229960003805 amantadine Drugs 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
• 208000006424 autoimmune oophoritis Diseases 0.000 description 2
• 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 2
• 206010071578 autoimmune retinopathy Diseases 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 208000000594 bullous pemphigoid Diseases 0.000 description 2
• 239000000480 calcium channel blocker Substances 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 210000005056 cell body Anatomy 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
• 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• LRUBQXAKGXQBHA-UHFFFAOYSA-N conduritol Chemical compound OC1C=CC(O)C(O)C1O LRUBQXAKGXQBHA-UHFFFAOYSA-N 0.000 description 2
• 229930191295 conduritol Natural products 0.000 description 2
• 201000004395 congenital heart block Diseases 0.000 description 2
• 201000003278 cryoglobulinemia Diseases 0.000 description 2
• 229960002806 daclizumab Drugs 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 229960002204 daratumumab Drugs 0.000 description 2
• 230000002999 depolarising effect Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 208000019479 dysautonomia Diseases 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 201000000708 eosinophilic esophagitis Diseases 0.000 description 2
• 150000002118 epoxides Chemical class 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 208000002980 facial hemiatrophy Diseases 0.000 description 2
• 125000001207 fluorophenyl group Chemical group 0.000 description 2
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 208000018090 giant cell myocarditis Diseases 0.000 description 2
• 150000002303 glucose derivatives Chemical class 0.000 description 2
• 239000003825 glutamate receptor antagonist Substances 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 208000007475 hemolytic anemia Diseases 0.000 description 2
• 208000002557 hidradenitis Diseases 0.000 description 2
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 2
• 201000006362 hypersensitivity vasculitis Diseases 0.000 description 2
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000010874 in vitro model Methods 0.000 description 2
• 201000008319 inclusion body myositis Diseases 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 229940074383 interleukin-11 Drugs 0.000 description 2
• 108010074109 interleukin-22 Proteins 0.000 description 2
• 229940028885 interleukin-4 Drugs 0.000 description 2
• 229940100601 interleukin-6 Drugs 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 229960004427 isradipine Drugs 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 229960004502 levodopa Drugs 0.000 description 2
• 201000011486 lichen planus Diseases 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 206010071570 ligneous conjunctivitis Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
• 229960004640 memantine Drugs 0.000 description 2
• 229940102859 methylene diphosphonate Drugs 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 206010063344 microscopic polyangiitis Diseases 0.000 description 2
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 230000003959 neuroinflammation Effects 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 2
• 229960005017 olanzapine Drugs 0.000 description 2
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
• 238000001543 one-way ANOVA Methods 0.000 description 2
• 201000005737 orchitis Diseases 0.000 description 2
• 201000005580 palindromic rheumatism Diseases 0.000 description 2
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 201000006292 polyarteritis nodosa Diseases 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 208000018290 primary dysautonomia Diseases 0.000 description 2
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
• 230000000529 probiotic effect Effects 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 229960003387 progesterone Drugs 0.000 description 2
• 239000000186 progesterone Substances 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 2
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
• CIIFKVFOVFJZDM-UHFFFAOYSA-N quinoline-8-carbonitrile Chemical compound C1=CN=C2C(C#N)=CC=CC2=C1 CIIFKVFOVFJZDM-UHFFFAOYSA-N 0.000 description 2
• HPQRQAOVNXWEEQ-UHFFFAOYSA-N quinoline-8-carboxamide Chemical compound C1=CN=C2C(C(=O)N)=CC=CC2=C1 HPQRQAOVNXWEEQ-UHFFFAOYSA-N 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 208000009169 relapsing polychondritis Diseases 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 229960004136 rivastigmine Drugs 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 208000010157 sclerosing cholangitis Diseases 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 230000002889 sympathetic effect Effects 0.000 description 2
• 229920006344 thermoplastic copolyester Polymers 0.000 description 2
• 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
• 238000001665 trituration Methods 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 238000009736 wetting Methods 0.000 description 2
• MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• WWFDJIVIDXJAQR-FFWSQMGZSA-N 1-[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(O)(=S)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](COP(O)(=S)O[C@@H]%11[C@@H](COP(O)(=S)O[C@@H]%12[C@@H](COP(O)(=S)O[C@@H]%13[C@@H](COP(O)(=S)O[C@@H]%14[C@@H](COP(O)(=S)O[C@@H]%15[C@@H](COP(O)(=S)O[C@@H]%16[C@@H](COP(O)(=S)O[C@@H]%17[C@@H](COP(O)(=S)O[C@@H]%18[C@@H](CO)O[C@H]([C@@H]%18OCCOC)n%18cc(C)c(=O)[nH]c%18=O)O[C@H]([C@@H]%17OCCOC)n%17cc(C)c(N)nc%17=O)O[C@H]([C@@H]%16OCCOC)n%16cnc%17c(N)ncnc%16%17)O[C@H]([C@@H]%15OCCOC)n%15cc(C)c(N)nc%15=O)O[C@H]([C@@H]%14OCCOC)n%14cc(C)c(=O)[nH]c%14=O)O[C@H]([C@@H]%13OCCOC)n%13cc(C)c(=O)[nH]c%13=O)O[C@H]([C@@H]%12OCCOC)n%12cc(C)c(=O)[nH]c%12=O)O[C@H]([C@@H]%11OCCOC)n%11cc(C)c(N)nc%11=O)O[C@H]([C@@H]%10OCCOC)n%10cnc%11c(N)ncnc%10%11)O[C@H]([C@@H]9OCCOC)n9cc(C)c(=O)[nH]c9=O)O[C@H]([C@@H]8OCCOC)n8cnc9c(N)ncnc89)O[C@H]([C@@H]7OCCOC)n7cnc8c(N)ncnc78)O[C@H]([C@@H]6OCCOC)n6cc(C)c(=O)[nH]c6=O)O[C@H]([C@@H]5OCCOC)n5cnc6c5nc(N)[nH]c6=O)O[C@H]([C@@H]4OCCOC)n4cc(C)c(N)nc4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(=O)[nH]c3=O)O[C@H]([C@@H]2OCCOC)n2cnc3c2nc(N)[nH]c3=O)O[C@H]1n1cnc2c1nc(N)[nH]c2=O WWFDJIVIDXJAQR-FFWSQMGZSA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• ZSIKVJNEGVNYIC-UHFFFAOYSA-N 2,4-dichloro-6-iodoquinazoline Chemical compound C1=C(I)C=CC2=NC(Cl)=NC(Cl)=C21 ZSIKVJNEGVNYIC-UHFFFAOYSA-N 0.000 description 1
• WAFPWZFANVRINJ-UHFFFAOYSA-N 2,4-dichloro-6-iodoquinoline Chemical compound C1=C(I)C=CC2=NC(Cl)=CC(Cl)=C21 WAFPWZFANVRINJ-UHFFFAOYSA-N 0.000 description 1
• DQEHUKWTOSTBGZ-UHFFFAOYSA-N 2-amino-5-bromo-3-(trifluoromethyl)benzoic acid Chemical compound NC1=C(C(O)=O)C=C(Br)C=C1C(F)(F)F DQEHUKWTOSTBGZ-UHFFFAOYSA-N 0.000 description 1
• YSBGYQUUOKRQAT-UHFFFAOYSA-N 2-amino-5-bromo-3-methoxybenzoic acid Chemical compound COC1=CC(Br)=CC(C(O)=O)=C1N YSBGYQUUOKRQAT-UHFFFAOYSA-N 0.000 description 1
• NRJFUIDAVYQYIY-UHFFFAOYSA-N 2-amino-5-iodo-3-(trifluoromethyl)benzoic acid Chemical compound NC1=C(C(=O)O)C=C(C=C1C(F)(F)F)I NRJFUIDAVYQYIY-UHFFFAOYSA-N 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
• COCFIBRMFPWUDW-UHFFFAOYSA-N 2-methylquinolin-4-amine Chemical compound C1=CC=CC2=NC(C)=CC(N)=C21 COCFIBRMFPWUDW-UHFFFAOYSA-N 0.000 description 1
• YHHJEBZFHVAVGK-UHFFFAOYSA-N 3-(4-iodo-2-methylanilino)-3-oxopropanoic acid Chemical compound CC1=CC(I)=CC=C1NC(=O)CC(O)=O YHHJEBZFHVAVGK-UHFFFAOYSA-N 0.000 description 1
• UJHSNFKCBJUMQQ-UHFFFAOYSA-N 3-(4-iodoanilino)-3-oxopropanoic acid Chemical compound OC(=O)CC(=O)NC1=CC=C(I)C=C1 UJHSNFKCBJUMQQ-UHFFFAOYSA-N 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• JYTSSQMVDQQBFH-UHFFFAOYSA-N 4-(benzylamino)-2-methylquinoline-8-carbonitrile Chemical compound C(C1=CC=CC=C1)NC1=CC(=NC2=C(C=CC=C12)C#N)C JYTSSQMVDQQBFH-UHFFFAOYSA-N 0.000 description 1
• XJYDUOHIXMNAJL-UHFFFAOYSA-N 4-(benzylamino)-2-methylquinoline-8-carboxamide Chemical compound C(C1=CC=CC=C1)NC1=CC(=NC2=C(C=CC=C12)C(=O)N)C XJYDUOHIXMNAJL-UHFFFAOYSA-N 0.000 description 1
• NITLQKCEJDSWEQ-UHFFFAOYSA-N 4-[(2,4-dichlorophenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=CC(=C1)Cl NITLQKCEJDSWEQ-UHFFFAOYSA-N 0.000 description 1
• AVGUPIURWQEZIV-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(C(=O)NC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1)Cl AVGUPIURWQEZIV-UHFFFAOYSA-N 0.000 description 1
• ZOQKUSPSFTZJRE-UHFFFAOYSA-N 4-[(2,6-dichlorophenyl)methoxy]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(COC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1)Cl ZOQKUSPSFTZJRE-UHFFFAOYSA-N 0.000 description 1
• DOAOUNZHTCSESY-UHFFFAOYSA-N 4-[(2,6-dichlorophenyl)methyl-methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(CN(C2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C)C(=CC=C1)Cl DOAOUNZHTCSESY-UHFFFAOYSA-N 0.000 description 1
• ZLSZDEARRQRWGO-UHFFFAOYSA-N 4-[(2,6-dichlorophenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1)Cl ZLSZDEARRQRWGO-UHFFFAOYSA-N 0.000 description 1
• OGPOHPVFXHHFJL-UHFFFAOYSA-N 4-[(2,6-dichlorophenyl)methylsulfanyl]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(CSC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1)Cl OGPOHPVFXHHFJL-UHFFFAOYSA-N 0.000 description 1
• FUFNYUQVVHGFLC-UHFFFAOYSA-N 4-[(2-chloro-6-fluorophenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1)F FUFNYUQVVHGFLC-UHFFFAOYSA-N 0.000 description 1
• CNMKNEFBMQWAQL-UHFFFAOYSA-N 4-[(2-chloro-6-methylphenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1)C CNMKNEFBMQWAQL-UHFFFAOYSA-N 0.000 description 1
• LQNJNDMPERULQF-UHFFFAOYSA-N 4-[(3,4-dimethylphenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound CC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=CC=1C LQNJNDMPERULQF-UHFFFAOYSA-N 0.000 description 1
• RSYRCNOZWSSPPA-UHFFFAOYSA-N 4-[(3,5-dichlorophenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=C(C=1)Cl RSYRCNOZWSSPPA-UHFFFAOYSA-N 0.000 description 1
• IKCVYWXPTWKNPM-UHFFFAOYSA-N 4-[(3,5-dimethylphenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound CC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=C(C=1)C IKCVYWXPTWKNPM-UHFFFAOYSA-N 0.000 description 1
• OYVZDAYGICYCFV-UHFFFAOYSA-N 4-[(3-chloro-2-fluorophenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC=1C(=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=CC=1)F OYVZDAYGICYCFV-UHFFFAOYSA-N 0.000 description 1
• RZPSSAZUOYMZPI-UHFFFAOYSA-N 4-[(3-chloro-2-methylphenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC=1C(=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=CC=1)C RZPSSAZUOYMZPI-UHFFFAOYSA-N 0.000 description 1
• QVBGGNMKVXKQEN-UHFFFAOYSA-N 4-[(3-methoxyphenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound COC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=CC=1 QVBGGNMKVXKQEN-UHFFFAOYSA-N 0.000 description 1
• XDIFUYRFLKFCHO-UHFFFAOYSA-N 4-[(4-chlorophenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound ClC1=CC=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=C1 XDIFUYRFLKFCHO-UHFFFAOYSA-N 0.000 description 1
• FJDURJGFJYLLGJ-UHFFFAOYSA-N 4-[[2-fluoro-3-(trifluoromethyl)phenyl]methylamino]-2-methylquinoline-8-carboxamide Chemical compound FC1=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C=CC=C1C(F)(F)F FJDURJGFJYLLGJ-UHFFFAOYSA-N 0.000 description 1
• BXZGSIDSJSGAJE-UHFFFAOYSA-N 4-[[2-fluoro-6-(trifluoromethyl)phenyl]methylamino]-2-methylquinoline-8-carboxamide Chemical compound FC1=C(CNC2=CC(=NC3=C(C=CC=C23)C(=O)N)C)C(=CC=C1)C(F)(F)F BXZGSIDSJSGAJE-UHFFFAOYSA-N 0.000 description 1
• AXVZSVDJWIROMR-UHFFFAOYSA-N 4-amino-2-methylquinoline-8-carboxamide Chemical compound NC1=CC(=NC2=C(C=CC=C12)C(=O)N)C AXVZSVDJWIROMR-UHFFFAOYSA-N 0.000 description 1
• JMZCPWFFBNLWIH-UHFFFAOYSA-N 4-aminoquinoline-8-carboxamide Chemical class C1=CN=C2C(C(=O)N)=CC=CC2=C1N JMZCPWFFBNLWIH-UHFFFAOYSA-N 0.000 description 1
• ZPOMTELIEJLKBS-UHFFFAOYSA-N 4-chloro-2-methylquinoline-8-sulfonamide Chemical compound C1=CC=C(S(N)(=O)=O)C2=NC(C)=CC(Cl)=C21 ZPOMTELIEJLKBS-UHFFFAOYSA-N 0.000 description 1
• GOPYMQFYUYWZBN-UHFFFAOYSA-N 4-chloro-6-iodo-1-methylquinolin-2-one Chemical compound ClC1=CC(N(C2=CC=C(C=C12)I)C)=O GOPYMQFYUYWZBN-UHFFFAOYSA-N 0.000 description 1
• XPJQSVAHSQNKCK-UHFFFAOYSA-N 4-chloro-8-methyl-6-(1,3-thiazol-5-yl)-1H-quinolin-2-one Chemical compound ClC1=CC(NC2=C(C=C(C=C12)C1=CN=CS1)C)=O XPJQSVAHSQNKCK-UHFFFAOYSA-N 0.000 description 1
• VMIOKIMSRSGXLM-UHFFFAOYSA-N 4-hydroxy-6-iodo-1,8-dimethylquinolin-2-one Chemical compound OC1=CC(N(C2=C(C=C(C=C12)I)C)C)=O VMIOKIMSRSGXLM-UHFFFAOYSA-N 0.000 description 1
• HZIHAAZAFYMRJY-UHFFFAOYSA-N 4-iodo-n,2-dimethylaniline Chemical compound CNC1=CC=C(I)C=C1C HZIHAAZAFYMRJY-UHFFFAOYSA-N 0.000 description 1
• IZVRDZGBMDYYQT-UHFFFAOYSA-N 4-iodo-n-methylaniline Chemical compound CNC1=CC=C(I)C=C1 IZVRDZGBMDYYQT-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
• 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
• CIUHQDCEPALBLE-UHFFFAOYSA-N 6-bromo-2,4-dichloro-8-methylquinazoline Chemical compound N1=C(Cl)N=C2C(C)=CC(Br)=CC2=C1Cl CIUHQDCEPALBLE-UHFFFAOYSA-N 0.000 description 1
• XZATUGDSXXVDFN-UHFFFAOYSA-N 6-bromo-4-[(2,6-dimethylphenyl)methylamino]-2-methylquinoline-8-carboxamide Chemical compound BrC=1C=C2C(=CC(=NC2=C(C=1)C(=O)N)C)NCC1=C(C=CC=C1C)C XZATUGDSXXVDFN-UHFFFAOYSA-N 0.000 description 1
• GNHFPZKAYFJEFV-UHFFFAOYSA-N 6-bromo-4-chloro-8-(trifluoromethyl)quinazoline Chemical compound BrC=1C=C2C(=NC=NC2=C(C=1)C(F)(F)F)Cl GNHFPZKAYFJEFV-UHFFFAOYSA-N 0.000 description 1
• AVNPVTTYPQZPRH-UHFFFAOYSA-N 6-bromo-4-chloro-8-methylquinazoline Chemical compound Cc1cc(Br)cc2c(Cl)ncnc12 AVNPVTTYPQZPRH-UHFFFAOYSA-N 0.000 description 1
• IVHVBVMREUQUCX-UHFFFAOYSA-N 6-bromo-8-methoxy-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C(OC)=CC(Br)=C2 IVHVBVMREUQUCX-UHFFFAOYSA-N 0.000 description 1
• RQFAJYPCPZEVHO-UHFFFAOYSA-N 6-bromo-n-phenylquinazolin-4-amine Chemical compound C12=CC(Br)=CC=C2N=CN=C1NC1=CC=CC=C1 RQFAJYPCPZEVHO-UHFFFAOYSA-N 0.000 description 1
• CFRVEJULVHOSOC-UHFFFAOYSA-N 6-fluoro-2-methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide Chemical compound FC=1C=C2C(=CC(=NC2=C(C=1)C(=O)N)C)NCC1=C(C(=CC=C1Cl)Cl)Cl CFRVEJULVHOSOC-UHFFFAOYSA-N 0.000 description 1
• NBSMJLABFCDYFQ-UHFFFAOYSA-N 6-iodo-1h-quinazoline-2,4-dione Chemical compound N1C(=O)NC(=O)C2=CC(I)=CC=C21 NBSMJLABFCDYFQ-UHFFFAOYSA-N 0.000 description 1
• BOUMFGOWEBRZCY-UHFFFAOYSA-N 6-iodo-1h-quinoline-2,4-dione Chemical compound N1C(=O)CC(=O)C2=CC(I)=CC=C21 BOUMFGOWEBRZCY-UHFFFAOYSA-N 0.000 description 1
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
• VPODZRLIOLZJAO-GOSISDBHSA-N 8-bromo-2-methyl-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]quinolin-4-amine Chemical compound BrC=1C=CC=C2C(=CC(=NC=12)C)N[C@@H]1CCCC2=CC=CC=C12 VPODZRLIOLZJAO-GOSISDBHSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 108050008264 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
• 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
• 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
• 239000012103 Alexa Fluor 488 Substances 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
• 241001134770 Bifidobacterium animalis Species 0.000 description 1
• 241000186016 Bifidobacterium bifidum Species 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• WASQSNKTFQJBNX-UHFFFAOYSA-N BrC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=C1 Chemical compound BrC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=C1 WASQSNKTFQJBNX-UHFFFAOYSA-N 0.000 description 1
• COFXKURUQWEVMW-UHFFFAOYSA-N BrC=1C=C(C=C2C(=CC(=NC=12)C)NCC1=C(C(=CC=C1Cl)Cl)Cl)F Chemical compound BrC=1C=C(C=C2C(=CC(=NC=12)C)NCC1=C(C(=CC=C1Cl)Cl)Cl)F COFXKURUQWEVMW-UHFFFAOYSA-N 0.000 description 1
• RDKZFIFMTYARNP-UHFFFAOYSA-N BrC=1C=C(C=C2C(=CC(=NC=12)C)O)F Chemical compound BrC=1C=C(C=C2C(=CC(=NC=12)C)O)F RDKZFIFMTYARNP-UHFFFAOYSA-N 0.000 description 1
• OUEZOAXGBRYCRE-UHFFFAOYSA-N BrC=1C=C2C(=CC(=NC2=C(C=1)C(=O)N)C)Cl Chemical compound BrC=1C=C2C(=CC(=NC2=C(C=1)C(=O)N)C)Cl OUEZOAXGBRYCRE-UHFFFAOYSA-N 0.000 description 1
• LXCYQHIRDFIKFE-UHFFFAOYSA-N BrC=1C=C2C(=CC(=NC2=C(C=1)C(=O)OC)C)O Chemical compound BrC=1C=C2C(=CC(=NC2=C(C=1)C(=O)OC)C)O LXCYQHIRDFIKFE-UHFFFAOYSA-N 0.000 description 1
• SYCWNEVEPCGGAG-UHFFFAOYSA-N BrC=1C=C2C(=CC(NC2=CC=1)=O)NC1CCOCC1 Chemical compound BrC=1C=C2C(=CC(NC2=CC=1)=O)NC1CCOCC1 SYCWNEVEPCGGAG-UHFFFAOYSA-N 0.000 description 1
• AECVPDPTTWRFKK-UHFFFAOYSA-N BrC=1C=C2C(=NC(=NC2=C(C=1)C)C)Cl Chemical compound BrC=1C=C2C(=NC(=NC2=C(C=1)C)C)Cl AECVPDPTTWRFKK-UHFFFAOYSA-N 0.000 description 1
• YSKFFAVRDSMWSU-UHFFFAOYSA-N BrC=1C=C2C(=NC(NC2=C(C=1)C)=O)NC1=CC(=C(C=C1)F)Cl Chemical compound BrC=1C=C2C(=NC(NC2=C(C=1)C)=O)NC1=CC(=C(C=C1)F)Cl YSKFFAVRDSMWSU-UHFFFAOYSA-N 0.000 description 1
• QUAIEXHUGJIEPR-UHFFFAOYSA-N BrC=1C=C2C(=NC=NC2=C(C=1)OC)Cl Chemical compound BrC=1C=C2C(=NC=NC2=C(C=1)OC)Cl QUAIEXHUGJIEPR-UHFFFAOYSA-N 0.000 description 1
• YBUUDJHUBCRVEX-UHFFFAOYSA-N BrC=1C=C2C(N=CNC2=C(C=1)C(F)(F)F)=O Chemical compound BrC=1C=C2C(N=CNC2=C(C=1)C(F)(F)F)=O YBUUDJHUBCRVEX-UHFFFAOYSA-N 0.000 description 1
• VKSVBALAFDTLNS-UHFFFAOYSA-N BrC=1C=CC=C2C(=CC(=NC=12)C)NCC1=C(C(=CC=C1Cl)Cl)Cl Chemical compound BrC=1C=CC=C2C(=CC(=NC=12)C)NCC1=C(C(=CC=C1Cl)Cl)Cl VKSVBALAFDTLNS-UHFFFAOYSA-N 0.000 description 1
• MKYLHDVLCJIYGS-UHFFFAOYSA-N BrC=1C=CC=C2C(=CC(=NC=12)C)NCC1=CC(=CC=C1)C Chemical compound BrC=1C=CC=C2C(=CC(=NC=12)C)NCC1=CC(=CC=C1)C MKYLHDVLCJIYGS-UHFFFAOYSA-N 0.000 description 1
• QGOKIFVPWOVDQN-UHFFFAOYSA-N BrC=1C=CC=C2C(=CC(=NC=12)C)NCC1=CC=C(C=C1)C Chemical compound BrC=1C=CC=C2C(=CC(=NC=12)C)NCC1=CC=C(C=C1)C QGOKIFVPWOVDQN-UHFFFAOYSA-N 0.000 description 1
• WSHNTXJUYWRFNF-UHFFFAOYSA-N BrC=1C=CC=C2C(=CC(=NC=12)C)SCC1=C(C=CC=C1Cl)Cl Chemical compound BrC=1C=CC=C2C(=CC(=NC=12)C)SCC1=C(C=CC=C1Cl)Cl WSHNTXJUYWRFNF-UHFFFAOYSA-N 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• YNURUHGJCLPBTI-UHFFFAOYSA-N CC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=C1)C Chemical compound CC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=C1)C YNURUHGJCLPBTI-UHFFFAOYSA-N 0.000 description 1
• FQHIDIVBSWARHL-UHFFFAOYSA-N CC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=1)C Chemical compound CC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=1)C FQHIDIVBSWARHL-UHFFFAOYSA-N 0.000 description 1
• HQCGEYSAKDPYTK-UHFFFAOYSA-N CC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1C Chemical compound CC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1C HQCGEYSAKDPYTK-UHFFFAOYSA-N 0.000 description 1
• 0 CCCNP(OCCC)(OCC([C@]1*)OC(C/C2=C\C=C\C(\C(N)=O)=C/C=C2)[C@]1F)=* Chemical compound CCCNP(OCCC)(OCC([C@]1*)OC(C/C2=C\C=C\C(\C(N)=O)=C/C=C2)[C@]1F)=* 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• QACJQHGIQZKMAR-UHFFFAOYSA-N Cc1cc(cc2C(=CC(=O)Nc12)NC3CCOCC3)c4cncs4 Chemical compound Cc1cc(cc2C(=CC(=O)Nc12)NC3CCOCC3)c4cncs4 QACJQHGIQZKMAR-UHFFFAOYSA-N 0.000 description 1
• MQZXDPKDXSHACX-UHFFFAOYSA-N Cc1cc(cc2c(Nc3ccc(F)c(Cl)c3)nc(O)nc12)c4cncs4 Chemical compound Cc1cc(cc2c(Nc3ccc(F)c(Cl)c3)nc(O)nc12)c4cncs4 MQZXDPKDXSHACX-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• QWKAQYSNYOTEEH-UHFFFAOYSA-N Cl.Cc1cc(NCc2ccc(Cl)c(Cl)c2)c2cccc(C(N)=O)c2n1 Chemical compound Cl.Cc1cc(NCc2ccc(Cl)c(Cl)c2)c2cccc(C(N)=O)c2n1 QWKAQYSNYOTEEH-UHFFFAOYSA-N 0.000 description 1
• ILYMJTBLTYHZRZ-UHFFFAOYSA-N ClC1=C(C(=O)NC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)Cl Chemical compound ClC1=C(C(=O)NC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)Cl ILYMJTBLTYHZRZ-UHFFFAOYSA-N 0.000 description 1
• ZQYAPGJPTPRQPC-UHFFFAOYSA-N ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)C Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)C ZQYAPGJPTPRQPC-UHFFFAOYSA-N 0.000 description 1
• WBJLJGSLFAOKQN-UHFFFAOYSA-N ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)Cl Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)Cl WBJLJGSLFAOKQN-UHFFFAOYSA-N 0.000 description 1
• HRPPNSOXAWEFKM-UHFFFAOYSA-N ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)F Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)F HRPPNSOXAWEFKM-UHFFFAOYSA-N 0.000 description 1
• NQSSAQNLDUVCLI-UHFFFAOYSA-N ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1F)F Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1F)F NQSSAQNLDUVCLI-UHFFFAOYSA-N 0.000 description 1
• FXOSGALJSMGCSP-UHFFFAOYSA-N ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=C1)Cl Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=C1)Cl FXOSGALJSMGCSP-UHFFFAOYSA-N 0.000 description 1
• AKNBGFHJVMQCFK-UHFFFAOYSA-N ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=C1 Chemical compound ClC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=C1 AKNBGFHJVMQCFK-UHFFFAOYSA-N 0.000 description 1
• PZIZLIXNKRNBEC-UHFFFAOYSA-N ClC1=C(COC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)Cl Chemical compound ClC1=C(COC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)Cl PZIZLIXNKRNBEC-UHFFFAOYSA-N 0.000 description 1
• TXOJTGGRRUJTMZ-UHFFFAOYSA-N ClC1=CC(NC2=C(C=C(C=C12)I)C)=O Chemical compound ClC1=CC(NC2=C(C=C(C=C12)I)C)=O TXOJTGGRRUJTMZ-UHFFFAOYSA-N 0.000 description 1
• DIQIHPOAQBETRT-UHFFFAOYSA-N ClC1=CC(NC2=CC=C(C=C12)C1=CN=CS1)=O Chemical compound ClC1=CC(NC2=CC=C(C=C12)C1=CN=CS1)=O DIQIHPOAQBETRT-UHFFFAOYSA-N 0.000 description 1
• VQYPFUKAEZMVOY-UHFFFAOYSA-N ClC1=CC(NC2=CC=C(C=C12)I)=O Chemical compound ClC1=CC(NC2=CC=C(C=C12)I)=O VQYPFUKAEZMVOY-UHFFFAOYSA-N 0.000 description 1
• MSGLMRZMMDBYHR-UHFFFAOYSA-N ClC1=CC=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C1 Chemical compound ClC1=CC=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C1 MSGLMRZMMDBYHR-UHFFFAOYSA-N 0.000 description 1
• NHPPIAUEYKDQFP-UHFFFAOYSA-N ClC1=NC2=C(C=C(C=C2C(=C1)Cl)I)C Chemical compound ClC1=NC2=C(C=C(C=C2C(=C1)Cl)I)C NHPPIAUEYKDQFP-UHFFFAOYSA-N 0.000 description 1
• IOLAPHDVKHCMOT-UHFFFAOYSA-N ClC=1C(=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1)C Chemical compound ClC=1C(=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1)C IOLAPHDVKHCMOT-UHFFFAOYSA-N 0.000 description 1
• HKUVFJURUDYFNC-UHFFFAOYSA-N ClC=1C(=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1)F Chemical compound ClC=1C(=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1)F HKUVFJURUDYFNC-UHFFFAOYSA-N 0.000 description 1
• BDSUVXMUZNUYPY-UHFFFAOYSA-N ClC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=1)Cl Chemical compound ClC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=C(C=1)Cl BDSUVXMUZNUYPY-UHFFFAOYSA-N 0.000 description 1
• HAEWPKYEZGLMFQ-UHFFFAOYSA-N ClC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1Cl Chemical compound ClC=1C=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C=CC=1Cl HAEWPKYEZGLMFQ-UHFFFAOYSA-N 0.000 description 1
• 102000005853 Clathrin Human genes 0.000 description 1
• 108010019874 Clathrin Proteins 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• 101710095468 Cyclase Proteins 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010072268 Drug-induced liver injury Diseases 0.000 description 1
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 206010015548 Euthanasia Diseases 0.000 description 1
• KKACOFARYWBNGG-UHFFFAOYSA-N FC(C(=O)O)(F)F.CC1=C(CNC=2C(=NC3=C(C=CC=C3C2)C(=O)N)C)C=CC=C1C Chemical compound FC(C(=O)O)(F)F.CC1=C(CNC=2C(=NC3=C(C=CC=C3C2)C(=O)N)C)C=CC=C1C KKACOFARYWBNGG-UHFFFAOYSA-N 0.000 description 1
• KVKLWUGAHHYHBZ-UHFFFAOYSA-N FC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)F Chemical compound FC1=C(CNC2=CC(=NC3=C(C=CC=C23)C#N)C)C(=CC=C1)F KVKLWUGAHHYHBZ-UHFFFAOYSA-N 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 229940123457 Free radical scavenger Drugs 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 239000001828 Gelatine Substances 0.000 description 1
• 108010072051 Glatiramer Acetate Proteins 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000727821 Homo sapiens RING1 and YY1-binding protein Proteins 0.000 description 1
• 206010021034 Hypometabolism Diseases 0.000 description 1
• BPHLYOUYORRKIY-UHFFFAOYSA-N IC1=CC(=C(C=C1)N(C(CC(=O)O)=O)C)C Chemical compound IC1=CC(=C(C=C1)N(C(CC(=O)O)=O)C)C BPHLYOUYORRKIY-UHFFFAOYSA-N 0.000 description 1
• KHKDEPIYYOVZMU-UHFFFAOYSA-N IC1=CC=C(C=C1)N(C(CC(=O)O)=O)C Chemical compound IC1=CC=C(C=C1)N(C(CC(=O)O)=O)C KHKDEPIYYOVZMU-UHFFFAOYSA-N 0.000 description 1
• XZLKREWFKRYFJL-UHFFFAOYSA-N IC1=CC=C(C=C1)N(C(CC(=O)OC)=O)C Chemical compound IC1=CC=C(C=C1)N(C(CC(=O)OC)=O)C XZLKREWFKRYFJL-UHFFFAOYSA-N 0.000 description 1
• SANDQTQGEFIVCQ-UHFFFAOYSA-N IC=1C=C2C(=CC(=NC2=C(C=1)C)O)O Chemical compound IC=1C=C2C(=CC(=NC2=C(C=1)C)O)O SANDQTQGEFIVCQ-UHFFFAOYSA-N 0.000 description 1
• RVWHCTLFVZCHOX-UHFFFAOYSA-N IC=1C=C2C(=NC(=NC2=C(C=1)C(F)(F)F)C)O Chemical compound IC=1C=C2C(=NC(=NC2=C(C=1)C(F)(F)F)C)O RVWHCTLFVZCHOX-UHFFFAOYSA-N 0.000 description 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
• 206010021263 IgA nephropathy Diseases 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 206010062018 Inborn error of metabolism Diseases 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 102100036721 Insulin receptor Human genes 0.000 description 1
• 206010023025 Ischaemic hepatitis Diseases 0.000 description 1
• 239000007836 KH2PO4 Substances 0.000 description 1
• 238000012313 Kruskal-Wallis test Methods 0.000 description 1
• 239000002211 L-ascorbic acid Substances 0.000 description 1
• 235000000069 L-ascorbic acid Nutrition 0.000 description 1
• 239000002139 L01XE22 - Masitinib Substances 0.000 description 1
• 240000001046 Lactobacillus acidophilus Species 0.000 description 1
• 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
• 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
• 244000199866 Lactobacillus casei Species 0.000 description 1
• 235000013958 Lactobacillus casei Nutrition 0.000 description 1
• 241000186840 Lactobacillus fermentum Species 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000019298 Lipocalin Human genes 0.000 description 1
• 108050006654 Lipocalin Proteins 0.000 description 1
• 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
• 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
• 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
• 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
• 108010062431 Monoamine oxidase Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
• 102000010722 N-Glycosyl Hydrolases Human genes 0.000 description 1
• 108010063372 N-Glycosyl Hydrolases Proteins 0.000 description 1
• HSSGXIXMNATULP-UHFFFAOYSA-N N1N=CC(=C1)CNC1=NC2=C(C=CC=C2C(=N1)NCC1=C(C=CC=C1C(F)(F)F)F)C(=O)N Chemical compound N1N=CC(=C1)CNC1=NC2=C(C=CC=C2C(=N1)NCC1=C(C=CC=C1C(F)(F)F)F)C(=O)N HSSGXIXMNATULP-UHFFFAOYSA-N 0.000 description 1
• NSTKLYAOBSRRSN-UHFFFAOYSA-N N1N=CC=C1CNC1=NC2=C(C=CC=C2C(=N1)NCC1=C(C=CC=C1C(F)(F)F)F)C(=O)N Chemical compound N1N=CC=C1CNC1=NC2=C(C=CC=C2C(=N1)NCC1=C(C=CC=C1C(F)(F)F)F)C(=O)N NSTKLYAOBSRRSN-UHFFFAOYSA-N 0.000 description 1
• 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
• DTQUSERWXBRVDD-UHFFFAOYSA-N NC1=CC(=NC2=C(C=CC=C12)C#N)C Chemical compound NC1=CC(=NC2=C(C=CC=C12)C#N)C DTQUSERWXBRVDD-UHFFFAOYSA-N 0.000 description 1
• 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• CSWOETBECUDEEP-UHFFFAOYSA-N O=C1Nc2ccc(cc2C(=C1)NC3CCOCC3)c4cncs4 Chemical compound O=C1Nc2ccc(cc2C(=C1)NC3CCOCC3)c4cncs4 CSWOETBECUDEEP-UHFFFAOYSA-N 0.000 description 1
• VADKTZLJDKIDJU-UHFFFAOYSA-N OC(=O)C(F)(F)F.Cc1ccc(CNc2cc(C)nc3c(cccc23)C(N)=O)c(C)c1 Chemical compound OC(=O)C(F)(F)F.Cc1ccc(CNc2cc(C)nc3c(cccc23)C(N)=O)c(C)c1 VADKTZLJDKIDJU-UHFFFAOYSA-N 0.000 description 1
• IXWVVYRQPQTROP-UHFFFAOYSA-N OC(=O)C(F)(F)F.NC(=O)c1cccc2c(NCc3c(F)cccc3C(F)(F)F)nc(nc12)N1Cc2[nH][nH]c(=O)c2C1 Chemical compound OC(=O)C(F)(F)F.NC(=O)c1cccc2c(NCc3c(F)cccc3C(F)(F)F)nc(nc12)N1Cc2[nH][nH]c(=O)c2C1 IXWVVYRQPQTROP-UHFFFAOYSA-N 0.000 description 1
• YAFOINOVKQSQAO-UHFFFAOYSA-N OC1=CC(N(C2=CC=C(C=C12)I)C)=O Chemical compound OC1=CC(N(C2=CC=C(C=C12)I)C)=O YAFOINOVKQSQAO-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 239000005662 Paraffin oil Substances 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000004788 Pars Planitis Diseases 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
• 229920005372 Plexiglas® Polymers 0.000 description 1
• 208000005374 Poisoning Diseases 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 1
• 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
• 102100029760 RING1 and YY1-binding protein Human genes 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
• UGDXRGXWUWVFLF-UHFFFAOYSA-N S1C=NC=C1N1C(C=CC2=CC=CC=C12)=O Chemical compound S1C=NC=C1N1C(C=CC2=CC=CC=C12)=O UGDXRGXWUWVFLF-UHFFFAOYSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 108010041191 Sirtuin 1 Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 244000057717 Streptococcus lactis Species 0.000 description 1
• 235000014897 Streptococcus lactis Nutrition 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
• 241000205098 Sulfolobus acidocaldarius Species 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 102000007238 Transferrin Receptors Human genes 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 101710123661 Venom allergen 5 Proteins 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 231100000354 acute hepatitis Toxicity 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 229960003318 alteplase Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000000702 anti-platelet effect Effects 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
• 229940127090 anticoagulant agent Drugs 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 230000004900 autophagic degradation Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 229960000794 baclofen Drugs 0.000 description 1
• 229930192649 bafilomycin Natural products 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
• 229960001081 benzatropine Drugs 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 229960002802 bromocriptine Drugs 0.000 description 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• 229960004205 carbidopa Drugs 0.000 description 1
• TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
• 229960002327 chloral hydrate Drugs 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 229960001653 citalopram Drugs 0.000 description 1
• 229930193282 clathrin Natural products 0.000 description 1
• 210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
• 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
• 235000017471 coenzyme Q10 Nutrition 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 210000005257 cortical tissue Anatomy 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000009699 differential effect Effects 0.000 description 1
• LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
• 229960004419 dimethyl fumarate Drugs 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 229960002768 dipyridamole Drugs 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229960001104 droxidopa Drugs 0.000 description 1
• QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 201000008865 drug-induced hepatitis Diseases 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
• 229950009041 edaravone Drugs 0.000 description 1
• 238000000835 electrochemical detection Methods 0.000 description 1
• FJZZPCZKBUKGGU-AUSIDOKSSA-N eliglustat Chemical compound C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 FJZZPCZKBUKGGU-AUSIDOKSSA-N 0.000 description 1
• 229960002856 eliglustat Drugs 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
• 229960003337 entacapone Drugs 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 229960000556 fingolimod Drugs 0.000 description 1
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 230000003371 gabaergic effect Effects 0.000 description 1
• 229960003980 galantamine Drugs 0.000 description 1
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960003776 glatiramer acetate Drugs 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• 150000002305 glucosylceramides Chemical class 0.000 description 1
• 230000000848 glutamatergic effect Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 102000050599 human TPCN1 Human genes 0.000 description 1
• 102000056347 human TPCN2 Human genes 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
• 229960004135 idebenone Drugs 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 108010039650 imiglucerase Proteins 0.000 description 1
• 229960002127 imiglucerase Drugs 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000012606 in vitro cell culture Methods 0.000 description 1
• 208000016245 inborn errors of metabolism Diseases 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 150000002475 indoles Chemical class 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229960004461 interferon beta-1a Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000008316 intracellular mechanism Effects 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 239000013038 irreversible inhibitor Substances 0.000 description 1
• 229950007752 isatuximab Drugs 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
• 229940017800 lactobacillus casei Drugs 0.000 description 1
• 229940012969 lactobacillus fermentum Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960001848 lamotrigine Drugs 0.000 description 1
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
• HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
• 229960004002 levetiracetam Drugs 0.000 description 1
• 238000009092 lines of therapy Methods 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
• 229960004655 masitinib Drugs 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• VMSDDOKBSSTEFY-UHFFFAOYSA-N methyl 3-(4-iodoanilino)-3-oxopropanoate Chemical compound COC(=O)CC(=O)NC1=CC=C(I)C=C1 VMSDDOKBSSTEFY-UHFFFAOYSA-N 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 238000001471 micro-filtration Methods 0.000 description 1
• 230000006756 microglial proliferation Effects 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 229960001512 miglustat Drugs 0.000 description 1
• UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000007625 mitochondrial abnormality Effects 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
• 229960003301 nivolumab Drugs 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 229950001015 nusinersen Drugs 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• 229950005751 ocrelizumab Drugs 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 238000009522 phase III clinical trial Methods 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960003089 pramipexole Drugs 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 238000012910 preclinical development Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 1
• ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
• 229960000245 rasagiline Drugs 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 229960004181 riluzole Drugs 0.000 description 1
• 229960001534 risperidone Drugs 0.000 description 1
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 229960001879 ropinirole Drugs 0.000 description 1
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
• 229960003179 rotigotine Drugs 0.000 description 1
• KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
• 238000009666 routine test Methods 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
• 229960003946 selegiline Drugs 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
• HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
• 229950007874 solanezumab Drugs 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 235000000891 standard diet Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 239000007940 sugar coated tablet Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 210000005222 synovial tissue Anatomy 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
• 229960000331 teriflunomide Drugs 0.000 description 1
• 229960005333 tetrabenazine Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
• 229960000488 tizanidine Drugs 0.000 description 1
• 229960004603 tolcapone Drugs 0.000 description 1
• MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 229960001032 trihexyphenidyl Drugs 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 229940102566 valproate Drugs 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1